TJC-265 / Newsoara Biopharma, TaiwanJ - LARVOL DELTA

[Announcement] Jingkai received a notice from its authorized partner in China, Hengyi Biotech, that TJC265 human phase I clinical trial review (IND) has been approved by the State Drug Administration of China. [Google translation] (Yahoo Finance) - "Jingkai was notified by its authorized partner in China, Hengyi Biotech, that TJC265's phase I clinical trial review (IND) in humans has been approved by the State Drug Administration of China....Other major events that affect the development of new drugs: Approval and implementation by the State Drug Administration of China Autotaxin Inhibitor's IPF (pulmonary fibrosis) phase I clinical trial."

New P1 trial • Idiopathic Pulmonary Fibrosis

【Announcement】Jingkai’s new drug TJC265 has been approved by Hengyi Biopharmaceuticals to the State Drug Administration of China as an applicant for Phase I clinical trial review (IND) [Google translation] (Yahoo News) - "Jingkai's new drug TJC265 has been approved by Hengyi Biopharmaceuticals to China State Drug Administration for Phase I clinical trial review (IND)....Uses: IPF (pulmonary fibrosis) effect of Autotaxin Inhibitor....Occurrence of other major events affecting the development of new drugs: filing an application for a Phase I human clinical trial review (IND)."

New P1 trial • Idiopathic Pulmonary Fibrosis